logo-loader
viewIntegumen

Integumen soars as it rolls out Labskin test to clone skin of clinical trial volunteers

The company said that the new test would cut the number of volunteers required for trials by 50%, reducing recruitment times and project management costs

Clinical trial
Labskin will also allow for double the number of possible skin tests during trials

Integumen PLC (LON:SKIN) shares soared on Friday after the firm announced the roll-out of a new Labskin test designed to clone the skin of volunteers in clinical trials.

The company said that the new test would cut the number of volunteers required for trials by 50%, reducing recruitment times and project management costs, and that when combined with human volunteers Labskin would allow for double the number of possible skin tests and make them more reliable and accurate.

WATCH: Integumen PLC to make 'transformational' move into clinical trials

The Labskin artificial intelligence (AI) platform would allow clients to receive real-time feedback, Integumen said.

Labskin, much like the name suggests, is laboratory-grown skin that is then used by cosmetic and pharmaceutical companies to test how their products react to human skin.

Gerard Brandon, Integumen’s chief executive, said the new Labskin test would “enhance the margins of medical device and clinical trial organisations on test subjects” and deliver “faster, more reliable and consistent results for their skin care, health care, wound care and pharmaceutical clients” at a lower cost.

In early afternoon, the company’s shares were up 16.4% at 1.9p.

Quick facts: Integumen

Price: 1.855 GBX

AIM:SKIN
Market: AIM
Market Cap: £18.2 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Integumen named herein, including the promotion by the Company of Integumen in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Multi-year deal with Parity Plc 'a match made in heaven' for Integumen -...

Integumen PLC's (LON:SKIN) Gerry Brandon caught up with Proactive London's Andrew Scott after unveiling a deal to deliver artificial intelligence software to clients of Parity Group, the data and people specialist. Brandon says the Drive4Growth partnership will provide Integumen access to...

4 days, 15 hours ago

2 min read